logo-loader

Belvoir gets profit benefit as financial adviser numbers grow 30%

Published: 03:06 07 Nov 2019 EST

Belvoir Group PLC - financial advisers
Belvoir increased the number of its financial advisers by a net 37 in 10 months

Belvoir Group PLC (LON:BLV) reported £1.9mln of gross contributions from mortgage broking in the first 10 months of the year and expects a further profit boost from a new exclusivity agreement signed with a Yorkshire-based chain of estate agents.

The property franchise group, which augmented its lettings and sales services with a financial services arm in 2016, has increased its number of financial advisers by 30% to 160 so far this year and has written 7,961 mortgages for independent estate agencies and via its group franchisees.

READ: Belvoir profits jump as it outperforms across key markets in first half

In the first six months of the year, the group reported a 23% rise in adjusted pre-tax profits to around £3mln, as financial services contributed more than a third of revenues.

Belvoir said its “strategic objective” is to increase the geographical coverage of financial services across the UK and its market share in existing territories by continuing its recruitment drive.

The new eight-year agreement is with Dacres, a 20-office estate agency, which Belvoir expects could support an increase from its current four advisers to 10 over the next two years and should contribute “around £100,000” to operating profit next year.

Belvoir chief executive Dorian Gonsalves said: “Our diversification into financial services is proving to be a real win-win for the group with growth arising from working with both our networks and independent agents.”

On taking on Dacres’ financial services activities he said: “Our financial services team based in Barnsley is well placed to support their network and is looking forward to working closely with their offices to build up the level of mortgage sales delivered to their clients.”

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 26 minutes ago